Notes de congrès/conférences

Atopic Dermatitis: a Short Summary

vendredi, avril 10th, 2015




Atopic Dermatitis is a chronic inflammatory condition of the skin which affects around 5% of the population. It is more prevalent in children living in industrialized nations with 15-20% affected. Initial presentation is under the age of four in 2/3 of cases. Global pollution and allergen-rich environment are some of the factors which explain high […]

Dark Circles (Infra-Orbital) Around the Eyes: a Combination Treatment

vendredi, avril 10th, 2015




Combination of Micro Needling and Trichloracetic acid 10% Peels in the Management of Infraorbital dark circles Markantoni V et al. AAD 2015 Annual Meeting, San Francisco CA – United States The pigmented skin of dark circles appears gives and impression of tiredness Dark circles are very frequent and although proposed mechanisms are proposed (CLICK HERE […]

Rosacea Treatment with Topical Ivermectin

vendredi, avril 10th, 2015




Comparative Efficacy and Safety of Ivermectin Cream 1% and Metronidazole 0.75% in the treatment of papulopustular Rosacea Taieb A. et al AAD 2015 Annual Meeting, San Francisco CA – United States Methods 962 subjects enrolled evaluation of recurrence 36 weeks after study done over 16 weeks Evaluation of Rosacea severity in both treated groups (metronidazole […]

Psoriasis: the role of microRNAs ?

vendredi, mars 27th, 2015




Introduction This article provides new potential molecular mechanisms providing interesting insights in the understanding of psoriasis. Cytokines and genetic findings constitute part of the findings in psoriasis and these have led to the development of the biologics. The following study talks about MicroRNAs miRNA are RNAs not translated into proteins: their size is between 19-25 […]

Omalizumab (Xolair) for Urticaria Treatment

mardi, mars 24th, 2015




Omalizumab (Xolair): recombinant humanized monoclonal antibody that binds to the free Immunoglobin IgE (produced byB lymphocytes), more specifically on the C3 domain of the IgE heavy chain complete, it block free IgE. Unlike ordinary anti-IgE antibodies, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the […]

Psoriasis Treatment with Biologics

mardi, mars 24th, 2015




Existing TNF-inhbitors: Adalimumab (Abbott) Infliximab (Janssen Bitotech and other biosimilars (generics) Etanercept (Amgen) Certolizumab (UCB) Il-17 antibodies Secukinumab (Cosentyx, Novartis): dosage: injected 300mg at weeks 0, 1, 2, 3, and 4 then 300mg or 150mg every 4 weeks, the doctor decides ! The price is the same for both doses ! Works in 3 weeks […]

Psoriasis treatment with « small molecules »

mardi, mars 24th, 2015




Available « small molecules »: Apremilast (Otezla) inhibits phosphodiesterase 4 (PDE4) exhibits anti-inflammatory properties apart from PDE4 action, its complete effects are not fully known but it is known (at the time of writing) that it modulates inflammation by reducing TNF-alpha, Il-2, IFN-gamma, leukotrienes and NO synthases. The effect appears to act through increased intracellular cAMP accumulation […]

Isotretinoin: an extreme effect on Muscular tissue

dimanche, mars 22nd, 2015




Severe rhabdomyolysis with Isotretinoin Therapy for Acne (Poster) Philips D et al. AAD 2015 Annual Meeting, San Francisco CA – United States Isotretinoin is  an oral vitamin D derivative most commonly used in the treatment of acne. Common side effects include skin and mucosal dryness, lipid elevations and elevated liver enzymes. According to some, the […]

Therapy with Oral Acitretin (a vitamin A derivative)

samedi, mars 21st, 2015




Acitretin: is a metabolite of etretinate is FDA-approved for use in psoriasis is less lipophilic than the former and fat storage (half life 120 days): It is highly highly toxic to embryos during pregnancies (teratogenic) and contraception in women must be used for at least 2 years (come say 3 three years) no safe dosage: […]

Acne scar treatment by drilling holes in the dermis

vendredi, mars 20th, 2015




Dermal needle treatment in acne scars (poster) Ertam I et al. AAD 2015 Annual Meeting, San Francisco CA – United States Acne scars are the long-term visible sequelae of more or less severe active acne. The demand for its treatment is in our experience is quite high and reaches 20% of those who had treatment […]

image description